Family Medicine & Primary Care Review

Full text

2/2026 vol. 28
Review paper

Hepatitis A in primary care practice

Zuzanna Waszak 1, 2
,
Jakub Marek Baran 3
,
Damian Grusiecki 4
,
Joanna Jarzębska 5
,
Maja Śmigielska 3

  1. Praski Hospital, Warsaw, Poland

  2. Students' Scientific Circle of Hygiene and Prevention, Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland

  3. Bielański Hospital, Warsaw, Poland

  4. Międzyleski Specialist Hospital, Warsaw, Poland

  5. Military Institute of Medicine – National Research Institute, Warsaw, Poland

Family Medicine & Primary Care Review 2026; 28(2): 209–214

DOI: https://doi.org/10.5114/fmpcr.2026.161520
Data publikacji online: 2026/06/22
Article file
17 FM&PCR 2 26 - R - Waszak - 2046 - Hepatitis A.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Abutaleb A, Kottilil S. Hepatitis A. Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention. Gastroenterol Clin North Am 2020; 49(2): 191–199, doi: 10.1016/j.gtc.2020.01.002.
  2. Nemes K, Persson S, Simonsson M. Hepatitis A Virus and Hepatitis E Virus as Food- and Waterborne Pathogens-Transmission Routes and Methods for Detection in Food. Viruses 2023; 15(8): 1725, doi: 10.3390/v15081725.
  3. Zhang L, Wang T, Zhou S, et al. Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities. Front Public Health 2025; 13: 1580863, doi: 10.3389/fpubh.2025.1580863.
  4. Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 2000; 18(Suppl 1): S68–S70, doi: 10.1016/S0264-410X(99)00469-7.
  5. European Centre for Disease Prevention and Control (ECDC). Hepatitis A virus in the EU/EEA, 1975–2014. Country profile: Poland. ECDC [Internet] 2016 [cited 23.03.2026]. Available from URL: https://www.ecdc.europa.eu/sites/default/files/media/en/healthtopics/hepatitis_A/Documents/hepatitis-a-eu-eea-country-profile-poland.pdf.
  6. Rzymski P, Zarębska-Michaluk D, Genowska A, et al. Trends of Hepatitis A Virus Infection in Poland: Assessing the Potential Impact of the COVID-19 Pandemic and War in Ukraine. Viruses 2024; 16(3): 469, doi: 10.3390/v16030469.
  7. Polański P, Kucharczyk B, Kondej B, et al. Hepatitis A in Poland in 2017 – epidemic increase cases. Przegl Epidemiol 2019; 73(4): 487–497, doi: 10.32394/pe.73.46.
  8. Zakład Epidemiologii Chorób Zakaźnych i Nadzoru, NIZP PZH–PIB, GIS. Zachorowania na wybrane choroby zakaźne w Polsce od 1 stycznia do 31 grudnia 2025 r. oraz w porównywalnym okresie 2024 r. NIZP–PZH–PIB [Internet] 2025 [cited 23.03.2026]. Available from URL: https://wwwold.pzh.gov.pl/oldpage/epimeld/2025/INF_25_12B.pdf (in Polish).
  9. Zakład Epidemiologii Chorób Zakaźnych i Nadzoru, NIZP PZH–PIB, GIS. Zachorowania na wybrane choroby zakaźne w Polsce od 1 stycznia do 15 marca 2026 r. oraz w porównywalnym okresie 2025 r. NIZP–PZH–PIB [Internet] 2026 [cited 23.03.2026]. Available from URL: https://wwwold.pzh.gov.pl/oldpage/epimeld/2026/INF_26_03A.pdf (in Polish).
  10. European Centre for Disease Prevention and Control. Hepatitis A. In: ECDC. Annual Epidemiological Report for 2022. ECDC [Internet] 2024 Feb [cited 23.03.2026]. Available from URL: https://www.ecdc.europa.eu/sites/default/files/documents/HEPA_AER_2022_Report.pdf.
  11. European Centre for Disease Prevention and Control. Rapid risk assessment – Multi-country outbreak of hepatitis A in the EU/EEA – 18 June 2025. ECDC [Internet] 2025 Jun [cited 23.03.2026]. Available from URL: https://www.ecdc.europa.eu/sites/default/files/documents/Multi-country_outbreak_of_HepA_June_2025.pdf.
  12. Migueres M, Lhomme S, Izopet J. Hepatitis A: epidemiology, high-risk groups, prevention and research on antiviral treatment. Viruses 2021; 13(10): 1900, doi: 10.3390/v13101900.
  13. Sander AL, Corman VM, Lukashev AN, et al. Evolutionary origins of enteric hepatitis viruses. Cold Spring Harb Perspect Med 2018; 8(12): a031690.
  14. World Health Organization. Hepatitis A [Internet]. World Health Organization 2025 Feb [cited 20.03.2026]. Available from URL: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a.
  15. Ntouva A, Sibal B, Balogun K, et al. Hepatitis A in primary care: working in partnership for diagnosis, management, and prevention of outbreaks. Br J Gen Pract 2019; 69(687): 521–522, doi: 10.3399/bjgp19X705965.
  16. Manka P, Verheyen J, Gerken G, et al. Liver failure due to acute viral hepatitis (A-E). Visc Med 2016; 32(2): 80–85, doi: 10.1159/000441495.
  17. Jayappa M, Kumar P, Goyal JP. Prolonged cholestasis after acute viral hepatitis: successfully treated with oral steroid. BMJ Case Rep 2020; 13(10): e234430, doi: 10.1136/bcr-2020-234430.
  18. Subramanian SK, Patel JM, Younes M, et al. Postinfectious autoimmune hepatitis-induced liver failure: a consequence of hepatitis A virus infection. ACG Case Rep J 2020; 7(8): e00441, doi: 10.14309/crj.0000000000000441.
  19. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny. Definicje przypadków chorób zakaźnych na potrzeby nadzoru epidemiologicznego. Wersja robocza 6c, styczeń 2025. Warszawa: NIZP–PZH; 2025 (in Polish).
  20. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70(4): 1–187, doi: 10.15585/mmwr.rr7004a1.
  21. World Health Organization. WHO position paper on hepatitis A vaccines – October 2022. Weekly Epidemiol Rec 97(40): 493–512 [Internet] 2022 [cited 23.03.2026]. Available from URL: https://iris.who.int/handle/10665/363397.
  22. Gabrielli F, Alberti F, Russo C, et al. Treatment Options for Hepatitis A and E: A Non-Systematic Review. Viruses 2023; 15(5): 1080, doi: 10.3390/v15051080.
  23. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69(5): 1–38, doi: 10.15585/mmwr.rr6905a1.
  24. Johne R, Scholz J, Falkenhagen A. Heat stability of foodborne viruses – Findings, methodological challenges and current developments. Int J Food Microbiol 2024; 413: 110582, doi: 10.1016/j.ijfoodmicro.2024.110582.
  25. Langan RC, Goodbred AJ. Hepatitis A. Am Fam Physician 2021; 104(4): 368–374.
  26. Polański P, Augustynowicz E. Szczepionka przeciw wzw A. Szczepienia.Info [Internet] 2026 Jan [cited 19.03.2026]. Available from URL: https://szczepienia.pzh.gov.pl/szczepionki/wzw-a/?strona=4#kto-i-kiedy-powinien-zostac-zaszczepiony-przeciw-wzw-a (in Polish).
  27. Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence. Hum Vaccin Immunother 2021; 17(5): 1496–1519, doi: 10.1080/21645515.2020.1819742.
  28. Duszczyk E, Wiercińska M. Szczepienie przeciwko WZW typu A. Medycyna Praktyczna – Szczepienia [Internet] 2023 Jul [cited 25.03.2026]. Available from URL: https://www.mp.pl/pacjent/szczepienia/szczepienia-i-szczepionki/66812,szczepienie-przeciwko-wzw-typu-a (in Polish).
  29. Bakker M, Bunge EM, Marano C, et al. Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. Expert Rev Vaccines 2016; 15(7): 829–851, doi: 10.1586/14760584.2016.1150182.
  30. Luo J, Wang X, Ma F, et al. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis A vaccines: a report on additional observations from a phase IV study. Clin Microbiol Infect 2019; 25(11): 1422–1427, doi: 10.1016/j.cmi.2018.11.005.
  31. Chappuis F, Farinelli T, Deckx H, et al. Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine 2017; 35(10): 1448–1454, doi: 10.1016/j.vaccine.2017.01.031.
  32. SAGE working group on hepatitis A vaccines. SAGE Hepatitis A vaccines systematic review report 9 March 2022. Geneva: WHO; 2022.
  33. Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357(17): 1685–1694, doi: 10.1056/NEJMoa070546.
  34. Girish V, Grant LM, John S. Hepatitis A. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2024 Oct [cited 22.03.2026]. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK459290/.
  35. Lemon SM, Ott JJ, Van Damme P, et al. Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol 2017; S0168-8278(17): 32278-X, doi: 10.1016/j.jhep.2017.08.034.
  36. Centers for Disease Control and Prevention (CDC). Clinical Care of Hepatitis A. CDC [Internet] 2025 Jan [cited 21.03.2026]. Available from URL: https://www.cdc.gov/hepatitis-a/hcp/clinical-care/index.html.
  37. Ahmad M, Rawat A, Farrukh S et al. Comparative analysis of oral ondansetron, metoclopramide, and domperidone for managing vomiting in children with acute gastroenteritis. Cureus 2023; 15(10): e47611, doi: 10.7759/cureus.47611.
  38. Patanwala AE, Amini R, Hays DP, et al. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010; 39(3): 330–336, doi: 10.1016/j.jemermed.2009.08.060.
  39. Freo U, Ruocco C, Valerio A, et al. Paracetamol: a review of guideline recommendations. J Clin Med 2021; 10(15): 3420, doi: 10.3390/jcm10153420.
  40. Hoption Cann SA. Paediatric acute hepatitis and therapeutic doses of paracetamol. Acta Paediatr 2024; 113(1): 19–21, doi: 10.1111/apa.16920.
  41. Park GC, Chung JW, Jang ES, et al. Association between adverse outcomes of hepatitis A and acetaminophen use: a population-based cohort study. Dig Liver Dis 2023; 55(10): 1368–1374, doi: 10.1016/j.dld.2023.03.017.
  42. Lu L, Chinese Society of Hepatology and Chinese Medical Association. Guidelines for the management of cholestatic liver diseases (2021). J Clin Transl Hepatol 2022; 10(4): 757–769, doi: 10.14218/JCTH.2022.00147.
  43. Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review. BMJ Support Palliat Care 2021; 11(2): 217–225, doi: 10.1136/bmjspcare-2020-002801.
  44. Gabrielli F, Crepaldi E, Cavicchioli A, et al. Itching for answers: a comprehensive review of cholestatic pruritus treatments. Biomolecules 2024; 14(10): 1227, doi: 10.3390/biom14101227.
  45. World Gastroenterology Organisation. Management of acute viral hepatitis. World Gastroenterology Organisation Practice Guidelines [Internet] 2003 Dec [cited 20.03.2026]. Available from URL: https://www.worldgastroenterology.org/guidelines/global-guidelines/management-of-acute-viral-hepatitis/acute-viral-hepatitis-english.
  46. Kalas MA, Chavez L, Leon M, et al. Abnormal liver enzymes: a review for clinicians. World J Hepatol 2021; 13(11): 1688–1698, doi: 10.4254/wjh.v13.i11.1688.
  47. Stravitz RT, Lee WM. Acute liver failure. Lancet 2019; 394(10201): 869–881, doi: 10.1016/S0140-6736(19)31894-X.
  48. Gholizadeh O, Akbarzadeh S, Ghazanfari Hashemi M, et al. Hepatitis A: viral structure, classification, life cycle, clinical symptoms, diagnosis error, and vaccination. Can J Infect Dis Med Microbiol 2023; 2023: 4263309, doi: 10.1155/2023/4263309.
  49. European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66(5): 1047–1081, doi: 10.1016/j.jhep.2016.12.003.
  50. McPhail MJ, Farne H, Senvar N, et al. Ability of King’s College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis. Clin Gastroenterol Hepatol 2016; 14(4): 516–525.e5, doi: 10.1016/j.cgh.2015.10.007.
  51. Ichai P, Legeai C, Francoza C, et al. French liver allocation system for patients with acute liver failure: a retrospective evaluation of criteria for urgent listing in France based on the Clichy-Villejuif score. Liver Transpl 2015; 21(4): 512–523, doi: 10.1002/lt.24092.
Copyright: © 2026 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with